Table 2 RNA-based therapies discussed in this review
From: RNA-based therapy in the management of lipid disorders: a review
RNA-based therapy | Target | Type | Modification |
|---|---|---|---|
CiVi007 [13] | PCSK9 | AsO | LNA |
Inclisiran [14] | PCSK9 | siRNA | GalNAc conjugate |
Mipomersen [15] | Apolipoprotein B100 | AsO | Ribose modified with addition of 2′-O-methoxyethyl |
Pelacarsen [16] | Apo(a) | AsO | GalNAc conjugate |
Olpasiran [17] | Apo(a) | siRNA | GalNAc conjugate |
Vupanorsen [18] | ANGPTL3 | AsO | GalNAc conjugate |
ARO-ANG3 [19] | ANGPTL3 | siRNA | GalNAc conjugate |
Volanesorsen [20] | ApoC3 | AsO | Ribose modified with addition of 2′-O-methoxyethyl |
ARO-APOC3 [19] | ApoC3 | siRNA | GalNAc conjugate |